Recardio at BIO International Convention 2026
- 1 day ago
- 1 min read
San Francisco, May 26, 2026 - Recardio Inc., a late-stage clinical biotechnology company developing therapies for cardiometabolic and other diseases, today announced that it is participating in the BIO International Convention 2026 in San Diego.
The conference is held annually and brings together the most innovative thinkers and leaders in biotechnology to provide opportunities through global partnerships, collaboration and thought leadership.
The conference is taking place on June 22-25, 2026 in San Diego.
Recardio is participating and presenting its latest advancements from its drug-based regenerative therapy and is giving a future outlook on new therapies and expansion programs.
About Recardio
Recardio Inc. is a late-stage clinical biotechnology company focused on developing therapies for cardiometabolic and other diseases through a therapeutic platform, designed for disease modification and regeneration.
The company is located in San Francisco, California, with operations in the USA and Europe.
Recardio’s lead drug candidate, dutogliptin, a DPP-IV inhibitor, has demonstrated efficacy in promoting endogenous disease-modifying cardiac regeneration and supporting tissue repair following cardiac injury. The FDA and EMA have approved the global pivotal Phase 3 HEAL-AMI clinical program in acute myocardial infarction for regulatory authorization in major markets.
In addition, the company is advancing multiple cardiometabolic programs in clinical and preclinical development.
For more information, visit: www.recardio.eu or contact pr@recardio.eu